Immune surveillance of tumors. Export

@article{citeulike:3152582, abstract = {The ability of the immune system to identify and destroy nascent tumors, and to thereby function as a primary defense against cancer, has been debated for many decades. Recent findings by a number of investigators in both mouse models of cancer and humans with cancer now offer compelling evidence that particular immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor suppressor mechanisms. This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments.}, address = {Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne 8006, Victoria, Australia.}, author = {Swann, J. B. and Smyth, M. J.}, citeulike-article-id = {3152582}, citeulike-linkout-0 = {http://dx.doi.org/10.1172/JCI31405}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/17476343}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=17476343}, doi = {10.1172/JCI31405}, issn = {0021-9738}, journal = {The Journal of clinical investigation}, keywords = {pathophys}, month = {May}, number = {5}, pages = {1137--1146}, posted-at = {2008-08-25 03:34:44}, priority = {2}, title = {Immune surveillance of tumors.}, url = {http://dx.doi.org/10.1172/JCI31405}, volume = {117}, year = {2007} }

TY - JOUR ID - citeulike:3152582 L3 - citeulike-article-id:3152582 N2 - The ability of the immune system to identify and destroy nascent tumors, and to thereby function as a primary defense against cancer, has been debated for many decades. Recent findings by a number of investigators in both mouse models of cancer and humans with cancer now offer compelling evidence that particular immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor suppressor mechanisms. This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments. IS - 5 JF - The Journal of clinical investigation SN - 0021-9738 AD - Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne 8006, Victoria, Australia. EP - 1146 TI - Immune surveillance of tumors. VL - 117 SP - 1137 KW - pathophys AU - Swann, JB AU - Smyth, MJ PY - 2007/05// UR - http://dx.doi.org/10.1172/JCI31405 ER -